Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 18/20 | 0.46 |
| ▸ | ACACA | Q13085 | 12/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5943065 | 0.89 | ACACB (0.51) | ACACBACACAALDH1A1THRB | |
| SCHEMBL1547410 | 0.89 | ACACB (0.53) | ACACBACACAALDH1A1 | |
| SCHEMBL735634 | 0.88 | ALDH1A1 (0.49) | ACACBACACAALDH1A1 | |
| SCHEMBL4686712 | 0.85 | ACACB (0.54) | ACACBACACATHRB | |
| SCHEMBL5942931 | 0.79 | RAB9A (0.43) | ACACBACACATHRB | |
| SCHEMBL29693773 | 0.76 | RAB9A (0.47) | ALDH1A1THRB | |
| SCHEMBL16838789 | 0.76 | RAB9A (0.47) | ALDH1A1THRB | |
| SCHEMBL29693760 | 0.76 | KDM4E (0.58) | ALDH1A1THRB | |
| SCHEMBL8332212 | 0.76 | KDM4E (0.58) | ALDH1A1THRB | |
| SCHEMBL27681568 | 0.75 | ALDH1A1 (0.47) | ACACBACACAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8748627-B2 | Acetyl-CoA carboxylase (ACC) inhibitors and their use in diabetes, obesity and metabolic syndrome | ABBVIE INC. (US) | 2014-06-10 | — | — | US | disclosed |
| US-20070225332-A1 | NOVEL ACETYL-COA CARBOXYLASE (ACC) INHIBITORS AND THEIR USE IN DIABETES, OBESITY AND METABOLIC SYNDROME | ABBVIE INC. | 2007-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225332-A1 | NOVEL ACETYL-COA CARBOXYLASE (ACC) INHIBITORS AND THEIR USE IN DIABETES, OBESITY AND METABOLIC SYNDROME | ACACA, ACACB, ACAT1 | ACACB 2/4885ACACA 1/4885ALDH1A1 330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.